| 1. |
潘志中, 伍小军, 姜武. 胃肠间质瘤分子分型的实践价值. 中华胃肠外科杂志, 2014, 17(4): 317-320.
|
| 2. |
Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch, 2001, 438(1): 1-12.
|
| 3. |
Pierie JP, Choudry U, Muzikansky A,et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg, 2001, 136(4): 383-389.
|
| 4. |
DeMatteo RP, Lewis JJ, Leung D,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg, 2000, 231(1): 51-58.
|
| 5. |
Plaat BE, Hollema H, Molenaar WM,et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol, 2000, 18(18): 3211-3220.
|
| 6. |
王亚农, 周烨. 手术治疗晚期胃肠间质瘤临床价值. 中国实用外科杂志, 2015, 35(4): 395-399.
|
| 7. |
Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1 640 patients. J Clin Oncol, 2010, 28(7): 1247-1253.
|
| 8. |
Demetri GD, von Oosterom AT, Garrett CR,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet, 2006, 368(9544): 1329-1338.
|
| 9. |
Blanke CD, Rankin C, Demetri GD,et al. Phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptors tyrosine kinase: S0033. J Clin Oncol, 2008, 26(4): 626-632.
|
| 10. |
Demetri GD, Reichardt P, Kang YK,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinb (GRID): and international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet, 2013, 381(9863): 295-302.
|
| 11. |
Fiore M, Plassini E, Fumagalli E,et al. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). Eur J Surg Oncol, 2009, 35(7): 739-745.
|
| 12. |
Blesius A, Cassier PA, Bertucci F,et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer, 2011, 11: 72.
|
| 13. |
Rutkowski P, Gronchi A, Hohenberger P,et al. Neoadjuvant Imatinib in locally advanced gastrointestinal stromal tumors (GIST): The EORTC STBSG experience. Ann Surg Oncol, 2013, 20(9): 2937-2943.
|
| 14. |
Holdsworth CH, Badawi RD, Manola JB,et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol, 2007, 189(6): W324-W330.
|
| 15. |
Joensuu H, Eriksson M, Sundby Hall K,et al. Onevs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA, 2012, 307(12): 1265-1272.
|
| 16. |
Demetri GD, von Mehren M, Blanke CD,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
|
| 17. |
Debiec-Rychter M, Sciot R, Le Cesne A,et al. KIT mutations and dose selection for imatinib in patients with advanced gastroin-testinal stromal tumours. Eur J Cancer, 2006, 42(8): 1093-1103.
|
| 18. |
An HJ, Ryu MH, Ryoo BY,et al. The effects of surgical cytore-duction prior to imatinib therapy on the prognosis of patients with advanced GIST. Ann Surg Oncol, 2013, 20(13): 4212-4218.
|
| 19. |
Raut CP, Posner M, Desai J,et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol, 2006, 24(15): 2325-2331.
|
| 20. |
Tielen R, Verhoef C, van Coevorden F,et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol, 2012, 10: 111.
|
| 21. |
Blanke CD, Rankin C, Benjamin R,et al. Long-term survival on S0033—a phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours (GISTs). Eur J Cancer, 2011, 47(suppl 1): Abstract 9404.
|
| 22. |
Du C, Zhou Y, Song C,et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China. Eur J Cancer, 2014, 50(10): 1772-1778.
|
| 23. |
Park SJ, Ryu MH, Ryoo BY,et al. The role of surgical resection following imatinib treatment in patients with recurrent or meta- static gastrointestinal stromal tumors: results of propensity score analyses. Ann Surg Oncol, 2014, 21(13): 4211-4217.
|
| 24. |
Rubio-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X,et al. Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol, 2015, 22(9): 2948-2957.
|
| 25. |
Bauer S, Rutkowski P, Hohenberger P,et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib-analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol, 2014, 40(4): 412-419.
|
| 26. |
DeMatteo RP, Maki RG, Singer S,et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg, 2007, 245(3): 347-352.
|
| 27. |
Gronchi A, Fiore M, Miselli F,et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg, 2007, 245(3): 341-346.
|
| 28. |
Zalcberg JR, Verweij J, Casali PG,et al. Outcome of patients with advanced gastrointestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer, 2005, 41(12): 1751-1757.
|
| 29. |
Gao X, Xue A, Fang Y,et al. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib. Sci Rep, 2016, 6: 22840.
|
| 30. |
Raut CP, Wang Q, Manola J,et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol, 2010, 17(2): 407-415.
|
1/5
WeChat